Studying factors that predict outcomes in Ewing sarcoma patients
Reviews records to see which factors relate to survival in Ewing sarcoma.
Plain-language title generated from the registry record
Registry title: Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma
Key facts
- Where
- Bologna, ItalySee the site
Where in Italy
- IRCCS Itituto Ortopedico RizzoliBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Ortopedico Rizzoli
- Trial code
- NCT06243588
- Record updated
- 5 March 2025
- Original description
assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma.Read full original descriptionShow less
Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma
assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma.
Identification of reliable prognostic factors could help to identify high-risk patients, which may require a different treatment and follow up.
Inclusion: Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021; Age ≥ 2 years; Diagnosis of Ewing Sarcoma; Patients with available clinical and imaging data.
Exclusion: At least one inclusion criterion not met.